옵션 체인은 다양한 행사가격과 만기일에 대한 Arch Biopartners의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Arch Biopartners에 대한 시장 심리를 평가합니다..

Arch Biopartners (OTC:ACHFF) 주식, 옵션 체인

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

Arch Biopartners Inc

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $19 to $17.

News

Price Target

Analyst Ratings

ITOS

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $17

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $105 to $110.

INSM

UBS Maintains Buy on Insmed, Raises Price Target to $110

UBS analyst Roger Boyd maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Buy and raises the price target from $250 to $260.

UBS Maintains Buy on Zscaler, Raises Price Target to $260

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced a deal to be <a href="https://in.benzinga.com/general/market-summary/25/03/44102644/walgreens-could-go-private-this-week-after-a-10-billion-deal-with-sycamore-partners-report">acquired by Sycamore Partners</a>.
What Happened: After the market close on Thursday, Walgreens announced it entered into a definitive agreement to be taken private by an entity affiliated with Sycamore Partners for $10 billion.
Walgreens shareholders will receive $11.45 per share in cash at closing. Shareholders are also eligible to receive up to $3 in cash per share from the future monetization of Walgreens&#8217; debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.
&#8220;While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus and change that is better managed as a private company. Sycamore will provide us with the expertise and experience of a partner with a strong track record of successful retail turnarounds,&#8221; said Tim Wentworth, CEO of Walgreens.
&#8220;The WBA Board considered all these factors in evaluating this transaction, and we believe this agreement provides shareholders premium cash value, with the ability to benefit from additional value creation going forward from monetization of the VillageMD businesses.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/03/44181200/broadcom-stock-surges-on-q1-earnings-beat-revenue-beat-strong-guidance-we-expect-continued-strength-in-ai-semiconductor-revenue">Broadcom Stock Surges On Q1 Earnings Beat, Revenue Beat, Strong Guidance: &#8216;We Expect Continued Strength In AI Semiconductor Revenue&#8217;</a>
Walgreens&#8217; board unanimously approved the proposed transaction, which is expected to close in the fourth quarter of 2025. Upon completion of the transaction, Walgreens will become a private company and the company&#8217;s common stock will be delisted from the Nasdaq.
Walgreens noted it will release its <a href="https://www.benzinga.com/calendars/earnings">second-quarter financial results</a> on April 8. Analysts currently expect the company to report earnings of 52 cents per share and revenue of $38.04 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were up 5.85% after hours, trading at $11.22 at the time of publication Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Walgreens Boots Alliance.

After-Hours Center

Movers

Walgreens Stock Rises As Company Inks $10B Deal To Go Private

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 5.67% on an annualized basis producing an average annual return of 13.79%. Currently, Gilead Sciences has a market capitalization of $144.34 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,300.17 today based on a price of $115.90 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741302909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GILD

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Retirement planning isn't exactly the most exciting topic. Until you realize you can actually get free money for investing in your future. <a href="https://www.benzinga.com/money/robinhood-review">Robinhood</a> is flipping the script on IRAs with an offer that's hard to ignore. Earn 3% extra on annual contributions when you <a href="https://www.benzinga.com/go/robinhood-gold-credit-card">subscribe to Robinhood Gold</a>, plus an uncapped 2% boost on transfers and rollovers until April 30. 
<ul>
<li><a href="https://www.benzinga.com/go/robinhood-retirement">Sign up for a Robinhood Retirement account now</a></li>
</ul>
<h2 class="wp-block-heading">Why Settle for Ordinary When You Can Boost Your IRA?</h2>
You work hard for your money, so why not make it work harder for you? With <a href="https://www.benzinga.com/go/robinhood-retirement">Robinhood's IRA</a>, every contribution gets an instant 3% boost when you&#8217;re a Robinhood Gold subscriber. And if you're rolling over funds from another retirement account, you'll get a 2% boost. No cap, no gimmicks, just extra cash added to your investments.
If you're serious about maxing out your IRA for 2025, there's another sweet deal: contribute the full amount by April 15, 2025, and you could snag an extra $420 in matching funds.
<h2 class="wp-block-heading">The Robinhood IRA Advantage</h2>
This isn't just another IRA. Robinhood is rewriting the rules with a platform built for simplicity, flexibility, and more money in your pocket.
<h3 class="wp-block-heading">Tax Advantages That Keep More Money in Your Pocket</h3>
Your <a href="https://www.benzinga.com/money/how-to-invest-your-ira">earnings in an IRA</a> grow tax-deferred or tax-free, depending on whether you choose a Traditional or Roth IRA. That means more of your money stays invested, compounding over time instead of going to the <a href="https://www.irs.gov/">IRS</a>.
<h3 class="wp-block-heading">Options Trading in a Tax-Advantaged Account</h3>
Not ready to retire from active investing? Robinhood lets qualified traders trade options on stocks and ETFs inside their IRA, with no commission or per-contract fees. That means you get the flexibility of options trading without the tax hit you'd face in a traditional brokerage account.
<h3 class="wp-block-heading">Already Have a 401(k)? Stack an IRA on Top</h3>
A 401(k) is great, but it might not be enough. If you're already maxing out your employer-sponsored plan, you can still contribute up to $7,000 in an IRA for 2025. More investment, more tax advantages, and with Robinhood, more free money with every contribution.
<h3 class="wp-block-heading">One Platform for Everything</h3>
Tired of tracking retirement accounts across different platforms? Robinhood makes it easy to find and consolidate your retirement savings in one place. Whether you&#8217;re rolling over an old 401(k) or moving funds from another IRA, the process is simple, fast, and now comes with a 2% cash boost on all transfers.
<h2 class="wp-block-heading">Who Should Consider a Robinhood IRA?</h2>
<ul>
<li>Investors who want more money upfront. Get an instant 3% boost on contributions</li>
<li>People who already <a href="https://www.benzinga.com/money/how-to-invest-your-401k">max out a 401(k)</a>. Stack an IRA on top for even greater tax benefits</li>
<li>Anyone looking for low-cost, commission-free investing. No hidden fees or per-contract costs</li>
<li>Self-employed workers or freelancers. No employer 401(k)? No problem. Robinhood's IRA puts you in control</li>
<li>Long-term investors who want to grow wealth tax-efficiently. Keep more of your gains over time</li>
</ul>
<h2 class="wp-block-heading">The Clock is Ticking</h2>
This isn't a forever deal. That 2% unlimited transfer boost disappears after April 30, and the $420 max-out match is only available if you contribute by April 15, 2025. The 3% instant match is here to stay for Robinhood Gold subscribers, but why wait? The sooner you contribute, the more time your money has to grow.
<ul>
<li><a href="https://www.benzinga.com/go/robinhood-retirement">Sign up for a Robinhood Retirement account now</a></li>
</ul>
Over 1,000,000 people have trusted Benzinga to help them choose their investing tools. Our experts are hard at work with constant updates as products &amp; markets change! Benzinga is a reader-supported publication. We may earn a commission from the advertisers associated with this article. This article is not sponsored.

Personal Finance

Robinhood's Retirement Account Just Got Even More Interesting

Maxim Group analyst Matthew Galinko downgrades Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) from Buy to Hold.

Downgrades

ARBE

Maxim Group Downgrades Arbe Robotics to Hold

Lake Street analyst Frank Takkinen maintains Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Hold and lowers the price target from $3 to $2.5.

SGHT

Lake Street Maintains Hold on Sight Sciences, Lowers Price Target to $2.5

Lake Street analyst Jacob Stephan maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and lowers the price target from $18 to $15.

CMPO

Lake Street Maintains Buy on CompoSecure, Lowers Price Target to $15

Lake Street analyst Jaeson Schmidt maintains Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) with a Buy and lowers the price target from $7 to $6.

INVE

Lake Street Maintains Buy on Identiv, Lowers Price Target to $6

The Ordinary Shares are expected to begin trading on the NYSE American under the ticker symbol "MCRP" on March 7, 2025. The Offering is expected to close on March 10, 2025, subject to satisfaction of customary closing conditions.

IPOs

MCRP

Micropolis Prices IPO Of 3.875M Ordinary Shares At $4.00 Per Share; To Begin Trading On NYSE American Under Ticker Symbol 'MCRP' On March 7

Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Buy and raises the price target from $54 to $58.

TARS

Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $58

The CFPB's dismissal follows its multi-year investigation which began prior to Upbound's acquisition of Acima in 2021. Acima will not pay any money, be required to change any business practices, or be subject to any injunctive or other relief, and the dismissal with prejudice ends the CFPB's challenge to the alleged business practices that were the subject of its investigation and lawsuit.
In connection with the CFPB's determination to drop its claims against Acima, Acima has agreed to dismiss the lawsuit it filed against the CFPB in the United States District Court for the Eastern District of Texas, which challenged the CFPB's authority to pursue those claims against Acima.

Legal

UPBD

Upbound Says Consumer Financial Protection Bureau Has Voluntarily Dismissed Lawsuit Against Its Unit Acima Leasing

Jones Trading analyst Matthew Erdner maintains Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) with a Buy and maintains $6 price target.

REAX

Jones Trading Maintains Buy on Real Brokerage, Maintains $6 Price Target

Scotiabank analyst Patrick Colville maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Sector Outperform and raises the price target from $225 to $242.

Scotiabank Maintains Sector Outperform on Zscaler, Raises Price Target to $242

DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $0.89 by 55.06 percent. This is a 23.21 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $470.91 million which beat the analyst consensus estimate of $447.00 million by 5.35 percent. This is a 15.69 percent increase over sales of $407.04 million the same period last year.

Earnings

Earnings Beats

DXPE

DXP Enterprises Q4 2024 Adj EPS $1.38 Beats $0.89 Estimate, Sales $470.91M Beat $447.00M Estimate

Trading Halt: Halt status updated at 5:40:00 PM ET: Quotation Resumption: News and Resumption Times

Scotiabank analyst Brandon Bingham maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Sector Perform and raises the price target from $51 to $53.

Scotiabank Maintains Sector Perform on Williams Companies, Raises Price Target to $53

Scotiabank analyst Nicholas Yulico maintains Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) with a Sector Outperform and raises the price target from $165 to $166.

WELL

Scotiabank Maintains Sector Outperform on Welltower, Raises Price Target to $166

Scotiabank analyst Allan Verkhovski maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Sector Perform and raises the price target from $240 to $245.

VEEV

Scotiabank Maintains Sector Perform on Veeva Systems, Raises Price Target to $245

Press Releases

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Health Care

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

General

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Comments

Arch Biopartners

Arch Biopartners (ACHFF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌